Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Becton, Dickinson and Company filings document the reporting, governance and capital-structure matters of a New York Stock Exchange-listed medical technology issuer. Its Form 8-K disclosures cover quarterly operating results, non-GAAP financial measures, dividend and capital allocation updates, executive appointments, compensatory arrangements and amendments to corporate by-laws.
The filing record also documents BD's completed separation of its Biosciences and Diagnostic Solutions business and related recast historical financial information presenting that business as discontinued operations. Capital-structure disclosures include registered common stock, NYSE-listed notes and tender-offer activity involving senior notes and debentures.
Becton Dickinson & Co. reported the equity holdings of its interim CFO, Vitor Roque, as of 12/05/2025. He beneficially owns 4,477 shares of common stock, which includes shares held directly and restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Roque also holds multiple grants of stock appreciation rights covering various amounts of common stock, with grant dates from 11/26/2018 through 11/26/2025, exercise prices ranging from $222.60 to $251.06, and expiration dates between 11/26/2027 and 11/26/2034. These rights vest in four annual installments beginning one year from each grant date and are held directly. A power of attorney authorizing Donna Kalazdy to sign on Roque’s behalf is also referenced.
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO & President of Life Sciences, reported a small sale of company stock. On 12/01/2025, he sold 75 shares of Becton Dickinson common stock at a price of $193.36 per share. After this transaction, he beneficially owned 16,580 shares of Becton Dickinson common stock in direct ownership. The filing notes that this sale was made under a pre-arranged Rule 10b5-1 trading plan that Feld adopted on February 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule.
Becton, Dickinson and Company reported an insider equity award for director Jacqueline Wright. On 12/01/2025, she acquired 180 shares of common stock through a grant of restricted stock units under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. The Form 4 shows the transaction as an acquisition at a stated price of $0, reflecting a stock-based compensation award rather than an open-market purchase. Following this grant, she beneficially owned 180 shares, held directly.
Becton, Dickinson and Company director reports stock award. A company director filed a Form 4 reporting the acquisition of 180 shares of Becton Dickinson common stock on 12/01/2025. The filing shows the transaction code "A," indicating an acquisition, at a price of $0 per share, and lists 180 shares beneficially owned directly after the transaction.
The footnote explains that these 180 shares represent restricted stock units granted under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. This reflects routine equity-based compensation rather than an open-market purchase or sale.
Becton Dickinson & Co. reported a new director-level insider with no current stake in the company’s stock. A Form 3 was filed for a board member of Becton Dickinson, indicating that as of 12/01/2025 the reporting person beneficially owns 0 shares of the company’s securities and holds no listed derivative securities such as options or warrants.
The filing confirms the individual’s role as a Director and that the report is filed on an individual basis, not as part of a group. A power of attorney is on file, allowing an authorized person to sign Section 16 reports on the director’s behalf.
Becton Dickinson & Co. director reports no beneficial ownership
A director of Becton Dickinson & Co. (BDX) filed an initial statement of beneficial ownership of securities. As of the event date of 12/01/2025, the reporting person states that they beneficially own no non-derivative securities of the company and list no derivative securities such as options or warrants. The filing is made on behalf of the director under a power of attorney, which is referenced as an attached exhibit.
Becton, Dickinson and Company insider plans small Rule 144 sale. A person identified as Michael Feld has filed a notice of proposed sale of 75 shares of Becton, Dickinson common stock, to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 12/01/2025. The 75 shares come from restricted stock units acquired on 08/20/2025. The filing notes that Becton, Dickinson had 285,418,551 common shares outstanding when this notice was prepared, which serves as a baseline ownership figure. The notice also lists prior Rule 10b5-1 sales during the past three months of 57 shares for gross proceeds of $10,602.57 and 58 shares for gross proceeds of $10,499.74. The signer represents that they are not aware of undisclosed material adverse information about the company.
Becton, Dickinson and Company filed an amended current report to update information about two newly elected directors. The amendment adds details on the compensation arrangements for Robert L. Huffines and Jacqueline Wright, who joined the Board of Directors effective December 1, 2025. Each will receive restricted stock units valued at $33,575, representing a prorated equity grant covering the period from their effective election date through BD’s 2026 Annual Meeting of Shareholders. All other information about their elections and the Board disclosed previously remains the same.
Becton, Dickinson and Company executive Pavan Mocherla, EVP & President, Greater Asia, reported equity awards in company stock. On 11/26/2025, he acquired 2,208 shares of common stock, described as restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan, at a reporting price of $0 per share. After this grant, he beneficially owned 5,055 shares directly.
On the same date, he also acquired 708 shares of common stock at a reporting price of $0 per share, identified as shares received upon vesting of performance-based equity awards, bringing his directly owned total to 5,763 shares. The filing is made on Form 4, which discloses changes in the insider’s beneficial ownership of Becton Dickinson & Co (BDX) common stock.
Becton, Dickinson and Company executive David Shan reported equity transactions in BDX stock. On 11/26/2025, he received 3,504 restricted stock units under the company’s 2004 Employee and Director Equity-Based Compensation Plan and 1,025 shares from vesting of performance-based equity awards, both at a stated price of $0 per share as these are compensation-related grants.
On the same date, 134 shares of common stock were withheld to cover taxes related to these vestings. After these transactions, Shan directly beneficially owned 8,970 shares of Becton Dickinson common stock. He is listed as an Executive Vice President and Chief ISC Officer, and the filing is made for one reporting person.